A Parkinson's Disease programme at Stem Plus in Sofia is €3,000–€8,000, versus roughly €18,400–€46,000 in the United States. About 11.5h from New York, inside the EU, visa-free.
If you are researching Parkinson's Disease treatment from the United States, the obstacle is usually access or cost: standard options have plateaued, and regenerative therapy at home runs to €18,400–€46,000. Stem Plus offers the same European GMP standard for a fraction of that — and an easy, mostly visa-free trip.
Parkinson's disease results from progressive loss of dopamine-producing neurons in the substantia nigra. Stem-cell research pursues two complementary routes: neurogenic cells differentiated toward dopamine neurons are studied to replace lost cells and restore dopamine signalling, while placental mesenchymal stem cells are explored for neuroprotection — slowing degeneration through anti-inflammatory and growth-factor secretion. Preclinical evidence suggests dopamine-releasing cells can reinnervate the striatum and that trophic factors may delay neuronal death. Key challenges are achieving cell survival, integration and functional restoration in a degenerating brain. Most trials are early-phase, with modest motor changes reported. It is delivered under a physician-led protocol and designed to complement your existing care.
| United States (home) | Stem Plus · EU | |
|---|---|---|
| Parkinson's Disease treatment | €18,400–€46,000 | €3,000–€8,000 |
| Regulation | varies | EU · GMP |
| Flight to Sofia | 11.5h from New York | — |
This note is general information for planning, not legal or medical advice. Confirm entry rules for your nationality before booking.
Cost ranges are indicative market figures for planning, not quotes.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם